• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Reed-Lane

    Flow Sciences

    Aphena Pharma Solutions

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Alcami

    PCI Pharma Services

    Flow Sciences

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Advancing Cell and Gene Therapies

    Amy DuRoss of Vineti discusses the key challenges cell and gene therapies face and advances to enhance safety, speed, and access

    Advancing Cell and Gene Therapies
    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • MedPharm
    • Mogene
    Kristin Brooks, Contract Pharma06.10.19
    Personalized therapeutics, such as cell and gene therapies and personalized cancer vaccines, are highly individualized and require specialized technology solutions to ensure patients receive and benefit from these drug therapies. At the start of the year, the U.S. FDA said that it expects to receive more than 200 new cell and gene therapy applications per year by 2025, and to approve 10 to 20 new cell and gene treatments each year.
     
    Cell and gene therapy technology company, Vineti has opened a new regional headquarters in Bethesda, MD, to help expand access to its Personalized Therapy Management platform in support of the increasing cell and gene therapy manufacturing facilities in the region, such as Paragon, Kite, Precigen, Bluebird, and Pfizer. Vineti’s third-party platform has undergone FDA and EMA regulatory review as part of a successful, expedited cell therapy filing.  
     
    Vineti recently entered partnership agreements with CareMetx to build patient-centered digital and service solutions to streamline cell and gene therapies, and with Marker Therapeutics to optimize logistics relating to Marker’s clinical stage pipeline of therapies in a safe and efficient manner.
     
    Contract Pharma spoke with Amy DuRoss, Vineti’s chief executive officer and co-founder, to discuss the key challenges cell and gene therapies face, and the advances being made to enhance safety and speed, making processes move more quickly and improving access to these highly individualized therapies.  –KB

    Contract Pharma: What are the key challenges pharma/biopharma companies face in the cell and gene therapy market?
     
    Amy DuRoss: Cell and gene therapies (CGT) are the most complex therapeutic processes that medicine has ever encountered. In contrast to the linear workflow of traditional medicines, the patient-centric CGT manufacturing process is more circular. A patient’s unique treatment must make it to him or her without any mistakes in Chain of Custody or Chain of Identity as it passes through numerous stages of the process. If there’s ever a mix-up and a patient receives the wrong cells, the resulting immune response and rejection could be extremely dangerous, or even fatal. Therefore, traceability is an essential patient safety component.
     
    Compounding this challenge is the fact that —unlike with small molecule drugs such as Lyrica and Zoloft —CGT treatments are difficult to batch process. Specifically, in these autologous therapies, where cells come from and are returned to the same patient, each patient is considered a “batch of one.” When a patient’s own tissues represent the starting material for a treatment, the extra care required can hamper efforts to manufacture these treatments at scale and with speed if enabling technologies are not in place. Allogeneic therapies — which are based on donor cells — can also be complex, because the donor material and final drug product may need to be matched to the intended patient in some way, often at a molecular level. Allogeneic therapies may also require multiple dosing, with each dose having the same stringent traceability requirements.
     
    Vineti’s Personalized Therapy Management (PTM) platform is a cloud-based, centralized solution, which provides complete orchestration of critical components in the CGT process for each patient’s unique treatment needs. The Vineti platform can track patient and donor material, workflow data, and drug product processes, in real-time, and coordinate the disparate steps of each process component so that they are fully integrated as a single therapeutic management process, instead of a fractured network of unequal parts. This orchestration is critical to patient safety and manufacturing efficiency.
     
    CP: What are the challenges moving from clinical to commercial scale manufacturing for cell and gene therapies?
     
    AD: Two key challenges are often at odds with each other — time and complexity.
     
    In advanced therapies, trial sponsors are under pressure to receive expedited status and move as quickly as possible. Traditional clinical trial phases are often shortened or merged. If you look at the clinical pipelines of many cell and gene therapy biopharmaceutical sponsors, you’ll note that many have products in phases such as “Phase I/II” or “Phase II/III.” Trials can expand from a handful of patients to dozens or even hundreds much faster than originally anticipated. According to data compiled by the Alliance for Regenerative Medicine, more than 90 therapies have received some type of accelerated status in the U.S., E.U., or Japan.
     
    At the same time, the patient journey and drug product process are more complex than ever before. Clinical trial operations and logistics require a new multi-dimensional, patient-centric paradigm that outstrips the capabilities of spreadsheets and manual management quickly.
     
    Data management also takes on new complexities. With traditional small molecule drugs, the pathway to commercialization often presents challenges to drug manufacturers during the regulatory approval process, as they attempt to gather and normalize data from the entire development journey to meet regulatory requests. However, these challenges are amplified during the CGT approval process, because the data stream is more complicated and, to a greater degree, is fragmented among the various components involved in sample handling throughout the manufacturing process.
     
    Approval of CGT treatments also carries a unique burden in that the software platform responsible for managing and orchestrating the therapeutic process must undergo regulatory approval as part of the drug product filing. That’s how critical a software system is to patient safety. These therapies represent the first time that regulatory authorities have added this type of systems-review requirement to the application process. 
     
    CP: Where have advances been made to enhance safety and speed, make processes move more quickly and improve access to CGT? 
     
    AD: There have been many advances – here are two of the most important ones.
     
    Improved access and safety for patients
    Digital, cloud-based solutions can greatly improve the safety — and speed — of the personalized medicine process. Systems such as Vineti allow for private and secure capture of critical patient data at each step in the value chain, such that each participant in the product journey can provide the right data at the right time to ensure product accuracy, safety and predictable product administration. At certain steps, critical data can be displayed to boost patient safety. At other steps, as appropriate or required by regulation, some data can be masked to preserve patient privacy. The simplification of this process and ease of deployment can allow a broader group of healthcare providers to prescribe and access these products for patients. The transparency built into this process can boost patient safety and confidence.
     
    Digital solutions can also make the process move more quickly for patients who are often very ill. Vineti’s platform can manage and orchestrate all the necessary patient information, for example, without requiring many error-prone and time-consuming paper forms, phone calls, and phone chains through different healthcare personnel. Courier logistics can be managed through the system for greater efficiency. These features can really streamline the process and keep things moving faster.
     
    Simplicity and familiarity for healthcare providers
    This is one of the most significant advances towards improving access to these therapies. Personalized therapeutics require workflows that cross boundaries and push stakeholders into new roles. Busy healthcare providers are now having to manage regulated, Good Manufacturing Practices (GMP) — and they are having to do so on behalf of a rapidly growing group of biopharmaceutical manufacturers. Therefore, they need to have confidence that these therapies can be managed safely on behalf of their patients.
     
    If these critical aspects aren’t as simple for them as possible, progress will slow. Digital solutions can simplify the complexity of the personalized medicine process, providing greater product accuracy, safety and predictability. The simplification of this process and ease of deployment can allow a broader group of healthcare providers to prescribe and access these products for patients.
     
    The Vineti system will be in use in almost 200 leading medical centers worldwide in 2019. Healthcare providers know our platform and know that we emphasize simplicity, usability, and transparency for their teams. That familiarity helps create a deeper sense of familiarity and trust.
     
    CP: How can key challenges to CGT processes be overcome?
     
    AD: Standardization and industrialization
    It may sound counterintuitive to standardize such deeply personalized products. But if we don’t standardize the parts of these processes that can be made predictable and repeatable, then we can’t industrialize this field. And if we can’t industrialize it, the field can’t grow to reach all the patients in need. “Mass customization” has been possible in other industries, and we need to start focusing there in cell and gene therapy.
     
    Digital solutions such as Vineti’s, for example, allow for accurate, transparent, repeatable Chain of Identity and Chain of Custody throughout the entire product journey to administration. This gives patients, physicians, and regulators confidence that the correct cells are being handled appropriately and that they can see the progress of each patient-centric product through to infusion.
     
    On an industry level, significant standards progress is being made in the CGT industry. The FDA-funded Standards Coordinating Body is driving ahead to get industry and agencies aligned, identify standards gaps, and start closing them. Vineti sits on the executive committee of this group and is actively helping to drive standardization, both with our clients and on an industry-wide level.
     
    Regulatory support
    As evidenced by the FDA’s statement in January 2019, anticipating more than 200 cell and gene therapy investigational new drugs per year by 2020 and 10 to 20 approvals a year by 2025, regulatory agencies are clearly ramping up for scale. We all need to make the work of these agencies as manageable and predictable as possible.
     
    In cell and gene therapies, for the first time, regulatory agencies have required that commercial filings include a description of the traceability system of record, since it’s so critical to patient safety. The Vineti platform has now been part of filing reviews by FDA and EMA regulators, and, in both cases, the reviews have been expedited. We’re working with our biopharmaceutical partners to establish a proven baseline of patient safety infrastructure with which agencies are familiar.
     
    Modernizing biotech and pharma IT options
    In biotech and pharma, the emphasis has always rightly been on the science. But as the science points to next-gen therapeutics such as cell and gene therapies, leaders are recognizing that enabling digital technologies are also required. Automation and cloud-based technologies, for example, are required in the highly distributed, complex CGT ecosystem.
     
    CGT also requires that many stakeholders and component systems collaborate. For example, healthcare providers need to time cell collections to be in sync with manufacturing capacity, so that collected cells don’t expire waiting for a manufacturing slot. Using orchestration tools such as Vineti’s PTM platform, the management of CGT manufacturing processes and patient populations has become increasingly more integrated and dependable. This is especially true as Vineti partners with increasing numbers of component systems, such as couriers, CROs, and hub services.
     
    By developing our platform as a centralized, cloud-based solution, we have also been able to provide advanced systems support to our clients, such as “always on” reliability and advanced cybersecurity. A cloud-based, centralized system gives us more agility and speed to identify issues or threats quickly and to apply preventive measures or fixes immediately and universally. With a centralized system, we have visibility into all process components simultaneously and in real time. This advanced, enterprise-grade approach also allows us to manage multiple client data sets, while preserving each individual client’s privacy and intellectual property.
     
    Better tracking of outcomes data
    In cell and gene therapy, the patient journey doesn’t end at infusion. Some therapies are multi-dose. All have long-term monitoring requirements that require detailed tracking, often for many years.
     
    These cell therapies are expensive due to their personalized nature; however, they can be very efficacious and possibly curative. The reimbursement landscape is ever shifting, especially in the United States, and outcomes-based reimbursement is still a developing concept. This reimbursement mechanism will require the proper data capture to ensure that all parties receive the required information to trigger reimbursement.
     
    Outcomes data can also provide critical insights that will help make these products better over time. However, these complex data need to be captured in ways that are manageable and usable. It’s one thing to have the data — it’s another to truly make use of it and cycle it back into R&D learnings.
     
    Integrating existing healthcare systems with these new cloud-based technologies, tasked with managing the product outside electronic health records, can bring the data into one accurate and single view for regulators, payer, and manufacturers.
     
    CP: What are some of the services provided under your partnership agreements?
     
    AD: Many of our partners are looking for expert input and collaborative solution development. We collaborate with our partners to understand their challenges, help map out their workflows, and develop the right solution for them. Vineti works with its partners to map their workflows, determine which modules they need, and outline how those modules should be configured. Our engineering teams enable and test the solution each partner needs. Also, GMP validation is essential for these systems, and Vineti handles this in partnership with our clients. We then provide training and work with our clients to get the system readied for “Go Live.”



     
    Amy is Co-founder and CEO of Vineti, a software technology company with the first commercial, cloud-based platform to expand patient access to life-saving cell and gene therapies. Amy is a long-time leader in biotechnology innovation. Prior to Vineti, Amy was Managing Director of GE Ventures, General Electric’s venture capital subsidiary, where she focused on creating new healthcare businesses in addition to venture investments. Before joining GE Ventures, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. Amy was also the Co-founder and Executive Director of Proposition 71, California's $3 billion stem cell research initiative passed in 2004, as well as Chief of Staff for the resulting state grant oversight agency, the California Institute for Regenerative Medicine.
    Related Searches
    • capacity
    • chief executive officer
    • Pharma IT
    • biopharma companies
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    MedPharm MedPharm
    Mogene Mogene
    Regis Custom Pharma Regis Custom Pharma
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    Vineti Opens New Regional HQ in Maryland Vineti Opens New Regional HQ in Maryland
    Lilly Lilly's CYRAMZA Gains Fifth Indication
    My Head is in The Cloud(s) My Head is in The Cloud(s)
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    SCHOTT Invests $1B in Pharmaceutical Packaging Biz SCHOTT Invests $1B in Pharmaceutical Packaging Biz
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review

    Related Online Exclusives

    • Biologics, Proteins, Vaccines | Clinical Trials
      Inside a Vaccine Trial

      Inside a Vaccine Trial

      Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
      Kristin Brooks, Managing Editor 02.05.21

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      The Future of Vaccines and Biologics

      The Future of Vaccines and Biologics

      Dr. Linda Marbán of Capricor Therapeutics discusses the advances in responding to infectious diseases.
      Kristin Brooks, Managing Editor, Contract Pharma 02.04.21

    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21


    • Biologics, Proteins, Vaccines
      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      CMOs expand and ‘repurpose’ capacities.
      S Harachand, Contributing Editor 10.20.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20

    • Biologics, Proteins, Vaccines | Drug Discovery
      Cell Therapy for Solid Tumors

      Cell Therapy for Solid Tumors

      Is base editing the solution for solid tumor-based cell therapy?
      Jonathan Frampton, Corporate Development Partner, Horizon Discovery 06.26.20


    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      COVID-19 Vaccine Response

      COVID-19 Vaccine Response

      ICON execs discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine
      Kristin Brooks, Contract Pharma 04.01.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trial Materials | Drug Development
      Newsmakers: Thermo Fisher Scientific

      Newsmakers: Thermo Fisher Scientific

      Leon Wyszkowski discusses the company’s recent investments, the challenges biopharma companies face, and future needs in the outsourcing space
      03.16.20

    • Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development
      COVID-19 Clinical Trials

      COVID-19 Clinical Trials

      The vaccines in development for COVID-19, who's developing them, and where they stand in the development process
      Kristin Brooks, Contract Pharma 03.10.20

    • Bio News | Biologics, Proteins, Vaccines | cGMP Manufacture
      Newsmakers: Vigene Biosciences

      Newsmakers: Vigene Biosciences

      Dr. Jeffrey Hung, Chief Commercial Officer, discusses Vigene’s new $20 million lab and strategic partnership with ASC Therapeutics
      Kristin Brooks, Contract Pharma 02.20.20


    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Industry News
      Outsourcing in the Cell & Gene Therapy Space

      Outsourcing in the Cell & Gene Therapy Space

      Specialized and coordinated capabilities aim to accelerate drug development and reduce risk for sponsors
      Kristin Brooks, Contract Pharma 02.04.20

    • Aseptic Processing | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish | Parenterals
      Contract Pharma’s 20th Anniversary Series: Vetter

      Contract Pharma’s 20th Anniversary Series: Vetter

      Oskar Gold of Vetter discusses vital changes in the industry and the science and technology needed to support advanced therapeutics
      Kristin Brooks, Contract Pharma 11.13.19

    • Analytical Services | Bioanalytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Formulation Development
      Contract Pharma’s 20th Anniversary Series: Ajinomoto Bio-Pharma

      Contract Pharma’s 20th Anniversary Series: Ajinomoto Bio-Pharma

      David Enloe of Ajinomoto Bio-Pharma Services shares his perspective on market changes over the years and the evolution of more integrated outsourcing
      Kristin Brooks, Contract Pharma 11.11.19

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Mule-Hide Products Co. Promotes Steven Litaker to Territory Manager
    Terra Firma, Wanhua Announce New Distribution Partnership
    Gelest CEO Elected to National Academy of Engineering
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login